NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.88+0.18 (+2.76%)
Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%
NextCure operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
NextCure's operating income for the twelve months ending Jun 30, 2026 was -$43.90M. For fiscal 2025 it was -$57.62M. The highest annual figure on record is -$23.20M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.62M | – |
| FY2024 | Dec 31, 2024 | -$59.75M | – |
| FY2023 | Dec 31, 2023 | -$67.64M | – |
| FY2022 | Dec 31, 2022 | -$75.91M | – |
| FY2021 | Dec 31, 2021 | -$70.77M | – |
| FY2020 | Dec 31, 2020 | -$41.23M | – |
| FY2019 | Dec 31, 2019 | -$37.48M | – |
| FY2018 | Dec 31, 2018 | -$23.20M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.77M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.24M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.23M | -309.9% |
| Q4 FY2020 | Dec 31, 2020 | -$16.24M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.80M | – |
| Q1 FY2020 | Mar 31, 2020 | $8.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.01M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.70M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.82M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.07M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.30M | – |
| Q1 FY2018 | Mar 31, 2018 | -$5.01M | – |
See a number that looks wrong?